HalcyGen works on IND
Friday, 18 July, 2008
Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.
The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.
It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.
According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
